Genset SA
Division of Merck KGaA
www.genxy.com
Latest From Genset SA
B-Ingelheim NASH Deal Boosts Pharmaxis’s Revitalization
The eagle has landed for Australian drug discoverer Pharmaxis in the form of a major deal with Boehringer Ingelheim for a non-alcoholic steatohepatitis (NASH) treatment, and the Sydney-based firm says it is ready to soar again following the transaction.
Deal Early, Less Often: ZymoGenetics' Broad Deal with Serono
Contemplating Consortia
Perlegen: Will Numbers Enable Pharmacogenomics
Company Information
- Industry
-
Biotechnology
-
Drug Discovery Tools
- Genomics-Proteomics
-
Drug Discovery Tools
- Pharmaceuticals
- Therapeutic Areas
- Non-Specific
- Alias(es)
- Ownership
- Private
- Headquarters
-
Worldwide
-
Europe
-
Western Europe
-
France
-
France
-
Western Europe
-
Europe
- Parent & Subsidiaries
- Merck KGaA
- Senior Management
-
Marc Vasseur, Chmn. & CEO
Agnes Le Saux-Narjoz, VP, Mktg.
Jeffery S Vick, MD, VP, Worldwide Bus. Dev.
John Ford, VP, Biopharmaceuticals - Contact Info
-
Genset SA
Phone: (33) 55 04 59 00
24 rue Royale
Paris, 75008
France
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice